This EGFR inhibitor study evaluates the immunogenic properties of three AD-specific B-cell epitopes (Tau229-237[pT231/pS235], pyroGluA3-8, and A37/38-42/43)

linked to five foreign T-cell epitopes (MVFP, TT, TBC Ag85B, PvT19, and PvT53) by immunizing inbred C57BL/6J (H-2b), SJL/J (H-2s2), and C3H/HeN (H-2k) mice. Two promising candidates with respect to MHC II restriction were selected, and two transgenic mouse models of AD, P301S (H-2b/k) and Tg2576 (H-2b/s) animals, were immunized with one B-cell epitope in combination with two T-cell epitopes. Responders displayed an enhanced immune response compared with wild-type animals, which supports the vaccine design and the vaccination strategy. The immune response was also characterized by specific IgG subtype titers, which revealed a strong polarization toward the humoral pathway for immunization of phospho-Tau, whereas for both A vaccines, a mixed cellular/humoral BEZ235 in vitro pathway response was observed. Despite the diversity

and unpredictability of the immunogenicity of the peptide vaccines, all three peptide vaccine formulations appear to be promising constructs for future evaluation of their therapeutic properties. Copyright (c) 2013 European Peptide Society and John Wiley & Sons, Ltd.”
“Ca2+ influx via voltage-dependent Ca(V)1/Ca(V)2 channels couples electrical signals to biological responses in excitable cells. Ca(V)1/Ca(V)2 channel blockers have broad biotechnological this website and therapeutic applications. Here we report a general method for developing novel genetically encoded calcium channel blockers inspired by Rem, a small G-protein that constitutively inhibits Ca(V)1/Ca(V)2 channels. We show that diverse cytosolic proteins (Ca-V beta, 14-3-3, calmodulin and CaMKII) that bind pore-forming alpha(1)-subunits can be converted into calcium channel blockers with tunable selectivity, kinetics and potency, simply by anchoring them to the plasma membrane. We term this method ‘channel inactivation induced by membrane-tethering of an associated protein’

(ChIMP). ChIMP is potentially extendable to small-molecule drug discovery, as engineering FK506-binding protein into intracellular sites within Ca(V)1.2-alpha(1C) permits heterodimerization-initiated channel inhibition with rapamycin. The results reveal a universal method for developing novel calcium channel blockers that may be extended to develop probes for a broad cohort of unrelated ion channels.”
“The objective of the present study was to evaluate the efficacy and mechanism of Crataegus oxycantha (COC) extract in preventing ischemia-reperfusion (IR) injury in an in vivo rat model of acute myocardial infarction induced by a 30-minute regional ischemia followed by 72 hours of reperfusion. The COC extract [100 mg/(kg body weight)] was administered 12 hours after the surgical procedure and then at 24-hour intervals for 3 days.